Stroumpoulis Konstantinos I, Pantazopoulos Ioannis N, Xanthos Theodoros T
Konstantinos I Stroumpoulis, Department of Experimental Surgery and Surgical Research, Medical School, University of Athens, 11527, Athens, Greece.
World J Cardiol. 2010 Sep 26;2(9):289-98. doi: 10.4330/wjc.v2.i9.289.
Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disease that affects the left ventricle. HCM can appear at any age, with the majority of the patients remaining clinically stable. When patients complain of symptoms, these include: dyspnea, dizziness, syncope and angina. HCM can lead to sudden cardiac death (SCD), mainly due to ventricular tachyarrhythmia or ventricular tachycardia. High-risk patients benefit from implantable cardioverter-defibrillators. Left ventricular outflow tract obstruction is not a rare feature in HCM, especially in symptomatic patients, and procedures that abolish that obstruction provide positive and consistent results that can improve long-term survival. HCM is the most common cause of sudden death in young competitive athletes and preparticipation screening programs have to be implemented to avoid these tragic fatalities. The structure of these programs is a matter of large debate. Worldwide registries are necessary to identify the full extent of HCM-related SCD.
肥厚型心肌病(HCM)是一种常见的遗传性心血管疾病,会影响左心室。HCM可在任何年龄出现,大多数患者临床症状保持稳定。当患者出现症状时,包括:呼吸困难、头晕、晕厥和心绞痛。HCM可导致心源性猝死(SCD),主要原因是室性快速心律失常或室性心动过速。高危患者可受益于植入式心脏复律除颤器。左心室流出道梗阻在HCM中并非罕见特征,尤其是有症状的患者,消除该梗阻的手术可提供积极且一致的结果,从而改善长期生存率。HCM是年轻竞技运动员猝死的最常见原因,必须实施赛前筛查计划以避免这些悲剧性死亡。这些计划的结构存在很大争议。有必要建立全球登记系统,以确定与HCM相关的心源性猝死的全貌。